262 related articles for article (PubMed ID: 26337393)
1. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
[TBL] [Abstract][Full Text] [Related]
2. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
3. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?
Taïeb D; Sebag F; Hubbard JG; Mundler O; Henry JF; Conte-Devolx B
Clin Endocrinol (Oxf); 2004 Jul; 61(1):102-8. PubMed ID: 15212651
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
5. Tumour size: the only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma.
Nguyen HH; Proye CA; Carnaille B; Combemale F; Pattou FN; Huglo D
Aust N Z J Surg; 1999 May; 69(5):350-3. PubMed ID: 10353549
[TBL] [Abstract][Full Text] [Related]
6. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
[TBL] [Abstract][Full Text] [Related]
7. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
8. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
9. A comparative immunohistochemical study of phaeochromocytomas and paragangliomas.
Fraga M; García-Caballero T; Antúnez J; Couce M; Beiras A; Forteza J
Histol Histopathol; 1993 Jul; 8(3):429-36. PubMed ID: 8358154
[TBL] [Abstract][Full Text] [Related]
10. Stathmin immunoreactivity in phaeochromocytomas and paragangliomas: differential expression between benign and malignant neoplasms.
Lin WC; Chen SC; Chuang YT; Kuo KL; Huang KH
Asian J Surg; 2011 Jan; 34(1):15-22. PubMed ID: 21515208
[TBL] [Abstract][Full Text] [Related]
11. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
[TBL] [Abstract][Full Text] [Related]
12. Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas.
Plouin PF; Gimenez-Roqueplo AP
Best Pract Res Clin Endocrinol Metab; 2006 Sep; 20(3):421-34. PubMed ID: 16980203
[TBL] [Abstract][Full Text] [Related]
13. Pre- and post-treatment distribution pattern of 123I-MIBG in patients with phaeochromocytomas and paragangliomas.
Sinclair AJ; Bomanji J; Harris P; Ross G; Besser GM; Britton KE
Nucl Med Commun; 1989 Aug; 10(8):567-76. PubMed ID: 2812639
[TBL] [Abstract][Full Text] [Related]
14. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
16. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
17. Imaging of pheochromocytoma and paraganglioma.
Brink I; Hoegerle S; Klisch J; Bley TA
Fam Cancer; 2005; 4(1):61-8. PubMed ID: 15883712
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
[TBL] [Abstract][Full Text] [Related]
20. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management.
Foo SH; Chan SP; Ananda V; Rajasingam V
Singapore Med J; 2010 May; 51(5):e89-93. PubMed ID: 20593136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
